What is William Blair’s Estimate for Medtronic Q3 Earnings?

Medtronic plc (NYSE:MDT) – Investment analysts at William Blair cut their Q3 2026 earnings per share (EPS) estimates for shares of Medtronic in a research note issued on Tuesday, November 19th. William Blair analyst M. Andrew now forecasts that the medical technology company will post earnings per share of $1.46 for the quarter, down from their previous forecast of $1.49. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q4 2026 earnings at $1.68 EPS.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.01. The business had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the company earned $1.25 EPS.

A number of other analysts have also issued reports on the stock. Daiwa America upgraded shares of Medtronic to a “strong-buy” rating in a report on Friday, August 23rd. Robert W. Baird dropped their target price on shares of Medtronic from $96.00 to $93.00 and set a “neutral” rating on the stock in a research note on Wednesday. Oppenheimer lifted their price target on shares of Medtronic from $92.00 to $94.00 and gave the company a “market perform” rating in a research note on Wednesday, August 21st. Stifel Nicolaus increased their price objective on Medtronic from $85.00 to $87.00 and gave the stock a “hold” rating in a research note on Wednesday, August 21st. Finally, JPMorgan Chase & Co. decreased their target price on Medtronic from $99.00 to $96.00 and set a “neutral” rating for the company in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $95.00.

Medtronic Stock Performance

Medtronic stock opened at $86.21 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.84 and a quick ratio of 1.61. The firm has a market capitalization of $110.56 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 2.42 and a beta of 0.84. Medtronic has a 1-year low of $75.96 and a 1-year high of $92.68. The company’s 50-day moving average is $88.99 and its 200 day moving average is $84.87.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Boyar Asset Management Inc. grew its position in Medtronic by 8.0% in the 3rd quarter. Boyar Asset Management Inc. now owns 5,213 shares of the medical technology company’s stock valued at $469,000 after buying an additional 385 shares during the last quarter. Anchor Investment Management LLC lifted its stake in shares of Medtronic by 1.2% in the 3rd quarter. Anchor Investment Management LLC now owns 107,518 shares of the medical technology company’s stock worth $9,680,000 after acquiring an additional 1,271 shares during the period. Tudor Financial Inc. purchased a new stake in shares of Medtronic in the third quarter valued at about $586,000. Chelsea Counsel Co. acquired a new position in shares of Medtronic during the third quarter worth about $45,000. Finally, Te Ahumairangi Investment Management Ltd raised its holdings in Medtronic by 4.1% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 52,321 shares of the medical technology company’s stock worth $4,684,000 after purchasing an additional 2,050 shares in the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.